Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

INTRODUCTION: Malignant mesothelioma (MM) is an aggressive disease with limited therapeutic options. In preclinical models, vascular endothelial growth factor (VEGF) stimulates MM proliferation. In MM patients, higher plasma VEGF levels correlate inversely with survival. Cediranib is an orally admin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lung Cancer
Autors principals: Campbell, Nicholas P., Kunnavakkam, Rangesh, Leighl, Natasha, Vincent, Mark D., Gandara, David R., Koczywas, Marianna, Gitlitz, Barbara J., Agamah, Edem, Thomas, Sachdev P., Stadler, Walter M., Vokes, Everett E., Kindler, Hedy L.
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319647/
https://ncbi.nlm.nih.gov/pubmed/22831987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2012.06.011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars